Why the study?
Does the Scn5a+/Δ mutation and treatment with flecainide or quinidine alter atrial arrhythmogenesis in a murine model of LQT3 syndrome?
Population
32 Langendorff-perfused murine hearts
Comparison
Programmed electrical stimulation and burst… vs Wild-type vs Scn5a+/Δ hearts, and baseline vs…
Design
Preclinical
Authors
Loading...
Reduced atrial arrhythmogenicity in LQT3-model hearts; hypothesis-generating and should not alter clinical practice.
Does the Scn5a+/Δ mutation and treatment with flecainide or quinidine alter atrial arrhythmogenesis in a murine model of LQT3 syndrome?
The KPQ mutation modelling LQT3 syndrome exerts inhibitory effects on atrial arrhythmogenesis, which is further modified by flecainide and quinidine through alterations in the critical interval between refractoriness and repolarization.
Dautova et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: